NIP
RNAM

Nicholas Investment Partners’s Avidity Biosciences RNAM Stock Holding History

Nicholas Investment Partners’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-69,570
Closed -$2.02M – 229
2024
Q4 		$2.02M Buy
+69,570
New +$2.91M 0.18% 158

Other funds holding RNAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nicholas Investment Partners's RNAM Position: Q1 2025 in Review

Nicholas Investment Partners sold out of Avidity Biosciences (RNAM) in Q1 2025, closing a stake of 69,570 shares — an estimated $2.02M sold.

Nicholas Investment Partners first reported a position in RNAM in Q4 2024 and held it in 1 quarter. The position peaked at $2.02M in Q4 2024. 220 funds tracked by Wall St. Rank hold RNAM as of Q1 2025.

  • Nicholas Investment Partners reported no remaining Avidity Biosciences position as of Q1 2025 after selling out during the quarter.
  • Nicholas Investment Partners sold 69,570 Avidity Biosciences shares in Q1 2025, an estimated $2.02M.
  • Nicholas Investment Partners first reported a position in Avidity Biosciences in Q4 2024 and held it in 1 quarter.
  • Nicholas Investment Partners's Avidity Biosciences position peaked at $2.02M in Q4 2024.
  • 220 funds tracked by Wall St. Rank held Avidity Biosciences as of Q1 2025.

Based on Nicholas Investment Partners's 13F filing for Q1 2025, filed 15 May 2025.